Received by email:

File: 17-11-28 VRT - News Release CTL Patent App PainOpioid-FINAL2r.pdf

     US Patent Office Acknowledges Provisional Patent
 Application for Use of Specific Cannabis Strain to Enhance
 Opioid Analgesia Filed by Veritas' Research Arm Cannevert
November 28, 2017, Vancouver, B.C.   Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), ("Veritas" or the "Company") announces its research arm, Cannevert Therapeutics Ltd. ("CTL")
filed a provisional patent application to US Patent and Trademark Office (the "USPTO") on September 13,
2017 for use of a specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement
letter from the USPTO was received recently which provided a filing number of US 62/558,021 for this
application.

Opioids are substances that are derived from the opium poppy plant. They bind to the human body's own
opioid receptors to provide pain relief or `analgesia' for patients with acute or chronic pain when prescribed
legally; morphine is an example opioid analgesic. Use of these drugs for a brief time is considered safe for
pain management. However, when they are overprescribed and/or frequently misused, they produce a
sense of euphoria along with relieving pain. Hence, drug dependence can occur despite using them as
prescribed over prolonged periods with the potential of fatal overdose. Opioid overdose contributed to more
than 33,000 deaths in 2015 according to US Centers for Disease Control and Prevention. Heroin and
fentanyl are the most widely known opioids for their illegal, recreational use, abuse potential and fatal
overdoses. Cannabis contains substances called cannabinoids that appear to bind to human body's own
cannabinoid receptors to also produce similar effects to those of the body's opioids in mediating analgesia
and behavioral effects. However, they do not have the same drug dependence or overdose potential.
When cannabinoids and opioids are combined, they appear to augment each other's effects synergistically.
Therefore, the combination may allow for opioids to be used at lower doses with fewer side effects for the
treatment of pain and related addiction. According Coherent Market Insights*, the global opioids market
was approximately USD $17b in 2015 and is forecasted to moderately increase to near USD $26b in 2024.
It indicates that legal cannabis is expected to impact the opioids market growth as it gets adopted as a safe
alternative pain relieving therapy to opioids and it is increasingly being used to address related addiction.
According to the World Drug Report 2016, approximately 17 million people suffered from opioid drug abuse.

Veritas CEO, Dr. Lui Franciosi stated, "We are pleased with Cannevert's latest submission to protect its
discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used
opioids while maintaining a good pain relieving effect for patients." Dr. Franciosi goes on to say, "This strain
could be also potentially useful in addressing the current fentanyl crisis throughout North America. If we're
targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that
clinicians can rely upon."

Also of note, Veritas Pharma has granted options to purchase 1.1 million shares to consultants of the
Company under the stock option plan at an exercise price of 81 cents for a period of one year from the date
of being granted.

*Global Opioids Agonist Drugs Market, By Product Type (Codeine, Fentanyl, Meperidine, Methadone,
Morphine, Hydrocodone), Therapeutic Application (Pain Management, Cough Treatment, Diarrhea
Treatment), and Geography - Trends, Analysis and Forecast till 2024 (Market Report   March 2017)
https://www.coherentmarketinsights.com/market-insight/opioids-market-135

                                                                                                   Page 1 of 2
 About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its
80% owned Cannevert Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is
the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars)
specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical
marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help
drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management
team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's
commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clinics,
insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the
Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF;
and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com

On behalf of the Board of Directors

"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under
our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

###
 

File: 17-11-28 VRT - News Release CTL Patent App PainOpioid-FINAL2r.docx

US Patent Office Acknowledges Provisional Patent Application for Use of Specific Cannabis Strain to Enhance Opioid Ana
--->lgesia Filed by Veritas' Research Arm Cannevert

November 28, 2017, Vancouver, B.C. - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
---> "Company") announces its research arm, Cannevert Therapeutics Ltd. ("CTL") filed a provisional patent application to 
--->US Patent and Trademark Office (the "USPTO") on September 13, 2017 for use of a specific cannabis strain to enhance th
--->e actions of opioid analgesics.  An acknowledgement letter from the USPTO was received recently which provided a filin
--->g number of US 62/558,021 for this application.

Opioids are substances that are derived from the opium poppy plant.  They bind to the human body's own opioid receptor
--->s to provide pain relief or 'analgesia' for patients with acute or chronic pain when prescribed legally; morphine is a
--->n example opioid analgesic.  Use of these drugs for a brief time is considered safe for pain management. However, when
---> they are overprescribed and/or frequently misused, they produce a sense of euphoria along with relieving pain.  Hence
--->, drug dependence can occur despite using them as prescribed over prolonged periods with the potential of fatal overdo
--->se.  Opioid overdose contributed to more than 33,000 deaths in 2015 according to US Centers for Disease Control and Pr
--->evention. Heroin and fentanyl are the most widely known opioids for their illegal, recreational use, abuse potential a
--->nd fatal overdoses. Cannabis contains substances called cannabinoids that appear to bind to human body's own cannabino
--->id receptors to also produce similar effects to those of the body's opioids in mediating analgesia and behavioral effe
--->cts.  However, they do not have the same drug dependence or overdose potential.  When cannabinoids and opioids are com
--->bined, they appear to augment each other's effects synergistically.  Therefore, the combination may allow for opioids 
--->to be used at lower doses with fewer side effects for the treatment of pain and related addiction.  According Coherent
---> Market Insights*, the global opioids market was approximately USD $17b in 2015 and is forecasted to moderately increa
--->se to near USD $26b in 2024.  It indicates that legal cannabis is expected to impact the opioids market growth as it g
--->ets adopted as a safe alternative pain relieving therapy to opioids and it is increasingly being used to address relat
--->ed addiction. According to the World Drug Report 2016, approximately 17 million people suffered from opioid drug abuse
--->.

Veritas CEO, Dr. Lui Franciosi stated, "We are pleased with Cannevert's latest submission to protect its discovery of 
--->a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining
---> a good pain relieving effect for patients."  Dr. Franciosi goes on to say, "This strain could be also potentially use
--->ful in addressing the current fentanyl crisis throughout North America.  If we're targeting pain or opioid addiction, 
--->we want to deliver a scientifically tested, standardized product that clinicians can rely upon."

Also of note, Veritas Pharma has granted options to purchase 1.1 million shares to consultants of the Company under th
--->e stock option plan at an exercise price of 81 cents for a period of one year from the date of being granted.

*Global Opioids Agonist Drugs Market, By Product Type (Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone
--->), Therapeutic Application (Pain Management, Cough Treatment, Diarrhea Treatment), and Geography - Trends, Analysis an
--->d Forecast till 2024 (Market Report - March 2017)
https://www.coherentmarketinsights.com/market-insight/opioids-market-135

About Veritas Pharma Inc. 
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Canneve
--->rt Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is the Company aim, through its inv
--->estment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD
--->, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses
---> a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in
---> CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. Th
--->e company's commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clini
--->cs, insurance industry and pharma, targeting multi-billion dollar global markets. 

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Sto
--->ck Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Fran
--->kfurt exchange under the ticker 2VP. 
For more information, please visit our website: veritaspharmainc.com 

On behalf of the Board of Directors

"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on 
--->SEDAR at www.sedar.com and on the CSE website at www.thecse.com. 

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785 
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com 

The CSE has not reviewed, nor approved or disapproved the content of this press release.

###